No Data
No Data
Independent Chairman of the Board of Ardelyx David Mott Buys 18% More Shares
Jefferies Maintains Ardelyx(ARDX.US) With Buy Rating, Announces Target Price $11
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
Ardelyx Appoints Joseph Reilly as Principal Accounting Officer
Ardelyx Insider Bought Shares Worth $996,598, According to a Recent SEC Filing
Ardelyx Down as H.C. Wainwright Downgrades Rating on Anticipated Xphozah Sales Drop
Tom’s Jerry : Why do you have so much faith in this stock? Is there any advantage that we don't know about?
Richard Fain Fan OP Tom’s Jerry : Yeah. An over reaction by pussy retail investors, we’ll take it to the Supreme Court. fundamentals still there. Top drug not even priced in. Trading at only 2x multiples. Big money gobbling this up.
交流道的小赢熊 : Yes. Long term investors of ARDX will know this move downwards is nothing. We have been through worse with it than this.
Buy and be patient. You'll be rewarded in future.
Richard Fain Fan OP 交流道的小赢熊 : Exactly, I know the company very well and what I'm holding